Summary
Genetic variability is responsible for some cardiac patients responding to Clopidogrel prophylaxix and therapy.
Analysis
This editorial plus 2 papers http://content.nejm.org/cgi/content/full/360/4/354 and
http://content.nejm.org/cgi/content/full/360/4/363 point out that genetic variations can be responsible why some do and some don't respond to this antithrombotic agent.
Remember what I have said in the past-PUT YOUR MONEY IN CO's THAT WORK OUT GENETIC VARIATIONS-Pharmacogenetics!!!!
This author consults with leading institutions through GLG
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
